CM Hospitalar (VVEO3) Q3 2025 earnings summary

Executive summary

• Achieved margin expansion and operational improvements despite a 3.8% year-over-year revenue decline in 3Q25, reflecting disciplined contract renegotiations, selectivity in Hospitals & Clinics, and a focus on profitability over volume.

• Gross margin reached its highest level in two years, supported by pricing initiatives, improved product mix, and cost controls.

• Cash generation and working capital management improved, with a shorter cash cycle and enhanced receivables collection.

• Net income was significantly boosted by the reversal of R$314.6 million in DIFAL tax provisions following favorable Supreme Court decisions.

• Ongoing strategic projects in inventory management, pricing, and SG&A reduction are expected to yield further gains.

Financial highlights

• Net revenue for 3Q25 was R$2,833.7 million, down 3.8% year-over-year; 9M25 revenue was R$8,434.1 million, down 2.5%.

• Gross profit increased 6.5% to R$415.6 million in 3Q25; gross margin rose 1.4 p.p. to 14.7%.

• Adjusted EBITDA grew 13.1% to R$172.9 million in 3Q25, with margin up 0.9 p.p. to 6.1%.

• Free cash flow in 3Q25 was R$166.9 million, up 28.8% year-over-year; 9M25 free cash flow reached R$291.6 million.

• Net debt at R$2,809.1 million, with leverage at 4.17x Adjusted EBITDA, the lowest since 4Q24.

Outlook and guidance

• Management expects continued margin and cash generation improvements, with further opportunities in working capital optimization and cost reduction.

• Early 4Q25 shows growth in main business lines, especially Hospitals and Clinics, with expectations for continued margin and cash flow improvements.

• Further gross margin gains anticipated through pricing initiatives and product mix optimization.

• Ongoing efforts to reduce SG&A and optimize working capital, including further reductions in accounts receivable days.

• Further improvements in inventory financing and freight optimization targeted by 1H26.